溶酶体降解靶向骨髓增殖性肿瘤中的突变钙网蛋白与血小板生成素受体
本研究探讨突变钙网蛋白(CRT)经溶酶体降解调控血小板生成素受体(MPL)的机制。突变CRT患者血小板表面MPL低,CRTDel52增加MPL溶酶体定位与降解;mTOR抑制剂降低CRTDel52与MPL水平、损害CRTDel52介导的细胞增殖,并减少MPN患者CD34+细胞集落形成与分化,对健康供者无此作用。
要点
- 突变CRT患者血小板表面MPL低于健康供者。
- CRTDel52增加MPL的溶酶体定位与降解。
- mTOR抑制剂降低CRTDel52与MPL并损害CRTDel52介导增殖。
核心结论
- 低表面MPL是突变CRT介导的骨髓增殖性肿瘤的生物标志物。
- 诱导CRTDel52与MPL降解是治疗干预的途径。
研究设计与样本
- 研究比较了突变CRT表达的MPN患者血小板与健康供者血小板的MPL表面水平。
- 研究检测了CRTDel52与MPL的溶酶体降解及mTOR抑制剂对CRTDel52、MPL和CD34+细胞的影响。
主要发现
- 与健康供者相比,突变CRT表达的MPN患者血小板表面MPL低。
- CRTDel52增加MPL的溶酶体定位与降解。
- mTOR抑制剂降低细胞CRTDel52与MPL水平及分泌的CRTDel52水平,并损害CRTDel52介导的细胞增殖。
- mTOR抑制减少MPN患者CD34+细胞的集落形成与分化,但不减少健康供者CD34+细胞的集落形成与分化。
临床怎么用
- 低表面MPL可作为突变CRT介导的MPN的生物标志物。
- 诱导CRTDel52与MPL降解是治疗干预的途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatic mutants of calreticulin (CRT) drive myeloproliferative neoplasms (MPNs) via binding to the thrombopoietin receptor (MPL) and aberrant activation of the JAK/STAT pathway. Compared with healthy donors, platelets from mutant CRT-expressing patients with MPN display low cell surface MPL. Additionally, coexpression of MPL with an MPN-linked CRT mutant (CRTDel52) reduces cell surface MPL, suggesting that CRTDel52 may induce MPL degradation. We show that lysosomal degradation is relevant to the turnover of CRTDel52 and MPL. Furthermore, CRTDel52 increases the lysosomal localization and degradation of MPL. Mammalian target of rapamycin (mTOR) inhibitors reduce cellular CRTDel52 and MPL, secreted CRTDel52 levels, and impair CRTDel52-mediated cell proliferation. mTOR inhibition also reduces colony formation and differentiation of CD34+ cells from patients with MPN but not from healthy donors. Together, these findings indicate that low-surface MPL is a biomarker of mutant CRT-mediated MPN and that induced degradation of CRTDel52 and MPL is an avenue for therapeutic intervention.
引用
- Kaur A, Venkatesan A, Kandarpa M, et al. Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms. Blood Adv. 2024. PMID: 38640435. doi:10.1182/bloodadvances.2023011432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。